Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4 and SRD5A2

Anu Loukola, Monica Chadha, Sharron G. Penn, David Rank, David V. Conti, Deborah Thompson, Mine Cicek, Brad Love, Vesna Bivolarevic, Qiner Yang, Yalin Jiang, David K. Hanzel, Katherine Dains, Pamela L. Paris, Graham Casey, John S. Witte

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Genes involved in the-testosterone biosynthetic pathway - such as CYP17A1, CYP3A4, and SRD5A2 - represent strong candidates for affecting prostate cancer. Previous work has detected associations between individual variants in these three genes and prostate cancer risk and aggressiveness. To more comprehensively evaluate CYP17A1, CYP3A4, and SRD5A2, we undertook a two-phase study of the relationship between their genotypes/haplotypes and prostate cancer. Phase I of the study first searched for single-nucleotide polymorphisms (SNPs) in these genes by resequencing 24 individuais from the Coriell Polymorphism Discovery Resource, 92-110 men from prostate cancer case-control sibships, and by leveraging public databases. In all, 87 SNPs were discovered and genotyped in 276 men from case-control sibships. Those SNPs exhibiting preliminary case-control allele frequency differences, or distinguishing (ie, 'tagging') common haplotypes across the genes, were identified for further study (24 SNPs in total). In Phase II of the study, the 24 SNPs were genotyped in an additional 841 men from case-control sibships. Finally, associations between genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2 and prostate cancer were evaluated in the total case-control sample of 1117 brothers from 506 sibships. Family-based analyses detected associations between prostate cancer risk or aggressiveness and a number of CYP3A4 SNPs (P-values between 0.006 and 0.05), a CYP3A4 haplotype (P-values 0.05 and 0.009 in nonstratified and stratified analysis, respectively), and two SRD5A2 SNPs in strong linkage disequilibrium (P=0.02). Undertaking a two-phase study comprising SNP discovery, haplotype tagging, and association analyses allowed us to more fully decipher the relation between CYP17A1, CYP3A4, and SRD5A2 and prostate cancer.

Original languageEnglish (US)
Pages (from-to)321-332
Number of pages12
JournalEuropean Journal of Human Genetics
Volume12
Issue number4
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP3A
Haplotypes
Single Nucleotide Polymorphism
Prostatic Neoplasms
Genotype
Genes
Biosynthetic Pathways
Linkage Disequilibrium
Gene Frequency
Testosterone
Siblings
Databases

Keywords

  • Association
  • CYP17A1
  • CYP3A4
  • Genetic susceptibility
  • Haplotyping
  • Prostate cancer
  • SRD5A2

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4 and SRD5A2. / Loukola, Anu; Chadha, Monica; Penn, Sharron G.; Rank, David; Conti, David V.; Thompson, Deborah; Cicek, Mine; Love, Brad; Bivolarevic, Vesna; Yang, Qiner; Jiang, Yalin; Hanzel, David K.; Dains, Katherine; Paris, Pamela L.; Casey, Graham; Witte, John S.

In: European Journal of Human Genetics, Vol. 12, No. 4, 04.2004, p. 321-332.

Research output: Contribution to journalArticle

Loukola, A, Chadha, M, Penn, SG, Rank, D, Conti, DV, Thompson, D, Cicek, M, Love, B, Bivolarevic, V, Yang, Q, Jiang, Y, Hanzel, DK, Dains, K, Paris, PL, Casey, G & Witte, JS 2004, 'Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4 and SRD5A2', European Journal of Human Genetics, vol. 12, no. 4, pp. 321-332. https://doi.org/10.1038/sj.ejhg.5201101
Loukola, Anu ; Chadha, Monica ; Penn, Sharron G. ; Rank, David ; Conti, David V. ; Thompson, Deborah ; Cicek, Mine ; Love, Brad ; Bivolarevic, Vesna ; Yang, Qiner ; Jiang, Yalin ; Hanzel, David K. ; Dains, Katherine ; Paris, Pamela L. ; Casey, Graham ; Witte, John S. / Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4 and SRD5A2. In: European Journal of Human Genetics. 2004 ; Vol. 12, No. 4. pp. 321-332.
@article{ddf9b42231284565b42650b981e1875d,
title = "Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4 and SRD5A2",
abstract = "Genes involved in the-testosterone biosynthetic pathway - such as CYP17A1, CYP3A4, and SRD5A2 - represent strong candidates for affecting prostate cancer. Previous work has detected associations between individual variants in these three genes and prostate cancer risk and aggressiveness. To more comprehensively evaluate CYP17A1, CYP3A4, and SRD5A2, we undertook a two-phase study of the relationship between their genotypes/haplotypes and prostate cancer. Phase I of the study first searched for single-nucleotide polymorphisms (SNPs) in these genes by resequencing 24 individuais from the Coriell Polymorphism Discovery Resource, 92-110 men from prostate cancer case-control sibships, and by leveraging public databases. In all, 87 SNPs were discovered and genotyped in 276 men from case-control sibships. Those SNPs exhibiting preliminary case-control allele frequency differences, or distinguishing (ie, 'tagging') common haplotypes across the genes, were identified for further study (24 SNPs in total). In Phase II of the study, the 24 SNPs were genotyped in an additional 841 men from case-control sibships. Finally, associations between genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2 and prostate cancer were evaluated in the total case-control sample of 1117 brothers from 506 sibships. Family-based analyses detected associations between prostate cancer risk or aggressiveness and a number of CYP3A4 SNPs (P-values between 0.006 and 0.05), a CYP3A4 haplotype (P-values 0.05 and 0.009 in nonstratified and stratified analysis, respectively), and two SRD5A2 SNPs in strong linkage disequilibrium (P=0.02). Undertaking a two-phase study comprising SNP discovery, haplotype tagging, and association analyses allowed us to more fully decipher the relation between CYP17A1, CYP3A4, and SRD5A2 and prostate cancer.",
keywords = "Association, CYP17A1, CYP3A4, Genetic susceptibility, Haplotyping, Prostate cancer, SRD5A2",
author = "Anu Loukola and Monica Chadha and Penn, {Sharron G.} and David Rank and Conti, {David V.} and Deborah Thompson and Mine Cicek and Brad Love and Vesna Bivolarevic and Qiner Yang and Yalin Jiang and Hanzel, {David K.} and Katherine Dains and Paris, {Pamela L.} and Graham Casey and Witte, {John S.}",
year = "2004",
month = "4",
doi = "10.1038/sj.ejhg.5201101",
language = "English (US)",
volume = "12",
pages = "321--332",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4 and SRD5A2

AU - Loukola, Anu

AU - Chadha, Monica

AU - Penn, Sharron G.

AU - Rank, David

AU - Conti, David V.

AU - Thompson, Deborah

AU - Cicek, Mine

AU - Love, Brad

AU - Bivolarevic, Vesna

AU - Yang, Qiner

AU - Jiang, Yalin

AU - Hanzel, David K.

AU - Dains, Katherine

AU - Paris, Pamela L.

AU - Casey, Graham

AU - Witte, John S.

PY - 2004/4

Y1 - 2004/4

N2 - Genes involved in the-testosterone biosynthetic pathway - such as CYP17A1, CYP3A4, and SRD5A2 - represent strong candidates for affecting prostate cancer. Previous work has detected associations between individual variants in these three genes and prostate cancer risk and aggressiveness. To more comprehensively evaluate CYP17A1, CYP3A4, and SRD5A2, we undertook a two-phase study of the relationship between their genotypes/haplotypes and prostate cancer. Phase I of the study first searched for single-nucleotide polymorphisms (SNPs) in these genes by resequencing 24 individuais from the Coriell Polymorphism Discovery Resource, 92-110 men from prostate cancer case-control sibships, and by leveraging public databases. In all, 87 SNPs were discovered and genotyped in 276 men from case-control sibships. Those SNPs exhibiting preliminary case-control allele frequency differences, or distinguishing (ie, 'tagging') common haplotypes across the genes, were identified for further study (24 SNPs in total). In Phase II of the study, the 24 SNPs were genotyped in an additional 841 men from case-control sibships. Finally, associations between genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2 and prostate cancer were evaluated in the total case-control sample of 1117 brothers from 506 sibships. Family-based analyses detected associations between prostate cancer risk or aggressiveness and a number of CYP3A4 SNPs (P-values between 0.006 and 0.05), a CYP3A4 haplotype (P-values 0.05 and 0.009 in nonstratified and stratified analysis, respectively), and two SRD5A2 SNPs in strong linkage disequilibrium (P=0.02). Undertaking a two-phase study comprising SNP discovery, haplotype tagging, and association analyses allowed us to more fully decipher the relation between CYP17A1, CYP3A4, and SRD5A2 and prostate cancer.

AB - Genes involved in the-testosterone biosynthetic pathway - such as CYP17A1, CYP3A4, and SRD5A2 - represent strong candidates for affecting prostate cancer. Previous work has detected associations between individual variants in these three genes and prostate cancer risk and aggressiveness. To more comprehensively evaluate CYP17A1, CYP3A4, and SRD5A2, we undertook a two-phase study of the relationship between their genotypes/haplotypes and prostate cancer. Phase I of the study first searched for single-nucleotide polymorphisms (SNPs) in these genes by resequencing 24 individuais from the Coriell Polymorphism Discovery Resource, 92-110 men from prostate cancer case-control sibships, and by leveraging public databases. In all, 87 SNPs were discovered and genotyped in 276 men from case-control sibships. Those SNPs exhibiting preliminary case-control allele frequency differences, or distinguishing (ie, 'tagging') common haplotypes across the genes, were identified for further study (24 SNPs in total). In Phase II of the study, the 24 SNPs were genotyped in an additional 841 men from case-control sibships. Finally, associations between genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2 and prostate cancer were evaluated in the total case-control sample of 1117 brothers from 506 sibships. Family-based analyses detected associations between prostate cancer risk or aggressiveness and a number of CYP3A4 SNPs (P-values between 0.006 and 0.05), a CYP3A4 haplotype (P-values 0.05 and 0.009 in nonstratified and stratified analysis, respectively), and two SRD5A2 SNPs in strong linkage disequilibrium (P=0.02). Undertaking a two-phase study comprising SNP discovery, haplotype tagging, and association analyses allowed us to more fully decipher the relation between CYP17A1, CYP3A4, and SRD5A2 and prostate cancer.

KW - Association

KW - CYP17A1

KW - CYP3A4

KW - Genetic susceptibility

KW - Haplotyping

KW - Prostate cancer

KW - SRD5A2

UR - http://www.scopus.com/inward/record.url?scp=11144357976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144357976&partnerID=8YFLogxK

U2 - 10.1038/sj.ejhg.5201101

DO - 10.1038/sj.ejhg.5201101

M3 - Article

VL - 12

SP - 321

EP - 332

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 4

ER -